Aptevo raises $8M, reports 85% remission for mipletamig in AML, adds APVO455

Aptevo Therapeutics Inc.

Gross proceeds of ~$8M from registered direct offering of 2.465M shares/pre-funded warrants and 12.325M common warrants at $3.25/unit.
Net proceeds ~$7.45M; funds for clinical development, working capital, and general corporate purposes.
Mipletamig (CD123xCD3) shows 85% remission rate in evaluable frontline AML patients in RAINIER trial; no CRS in first two cohorts.
Cohort 3 nears full enrollment at highest dose; mipletamig triplet therapy enables transplant in previously ineligible patient.
New preclinical candidate APVO455 (Nectin-4xCD3) added to CD3-targeted pipeline using CRIS-7 domain; targets solid tumors.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.